Co-Authors
This is a "connection" page, showing publications co-authored by GREGORY N FULLER and JOHN FREDERICK DE GROOT.
Connection Strength
1.943
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.181
-
Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000.
Score: 0.168
-
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.
Score: 0.138
-
Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. 2016 May 03; 7(18):26793-805.
Score: 0.137
-
Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10.
Score: 0.131
-
Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol. 2014 Mar; 16(3):409-13.
Score: 0.116
-
Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014 Jan 01; 20(1):187-98.
Score: 0.116
-
Moving toward molecular classification of diffuse gliomas in adults. Neurology. 2012 Oct 30; 79(18):1917-26.
Score: 0.108
-
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48.
Score: 0.107
-
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010 Mar; 12(3):233-42.
Score: 0.089
-
Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology. 2009; 76(1):10-8.
Score: 0.082
-
Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol. 2008 Jun; 88(2):121-33.
Score: 0.079
-
The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res. 2005 Mar 01; 65(5):1934-40.
Score: 0.063
-
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.
Score: 0.056
-
An expedited strategy for accurate and timely integrated molecular diagnosis of?gliomas. Neuro Oncol. 2023 04 06; 25(4):808-809.
Score: 0.056
-
Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac129.
Score: 0.053
-
Clinical and survival characteristics of primary and secondary gliosarcoma patients. Clin Neurol Neurosurg. 2022 03; 214:107146.
Score: 0.051
-
A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146.
Score: 0.047
-
Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract. 2020 Dec; 7(6):613-619.
Score: 0.045
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.045
-
A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res. 2018 12 15; 24(24):6288-6299.
Score: 0.040
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
Score: 0.035